In the packed oncolytic virus space, a German biotech with a unique approach makes investors reach deeper into their wallets

When Abalos Therapeutics closed its $12 million Series A round two years ago, the company was essentially “two guys, a key and one room,” CEO Marcus Kostka jokes.

Now, the startup is 13 employees large, with an arenavirus-based cancer program nearly ready for the clinic. And that, according to...

Click to view original post